Research Papers

This database includes peer-reviewed publications authored or funded by TB Alliance. Use the tags on the right to filter by subject, or search for a particular author or term using the search bar.

Displaying 187 papers

Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial

5/2024 - Lancet Infectious Diseases

Author(s): Muge Cevik, MD Lindsay C Thompson, MPhil Caryn Upton, MD Valéria Cavalcanti Rolla Mookho Malahleha, MD Blandina Mmbaga, PhD Nosipho Ngubane, MD Zamzurina Abu Bakar, MD Mohammed Rassool, MD Ebrahim Variava, MD Rodney Dawson, MD Suzanne Staples, DPhil Umes

Tags: Clinical Development, Clinical Trial Results, Global Pipeline, MDR-TB, Moxifloxacin, Pretomanid/PA-824, Pyrazinamide

Prevalence and genetic basis of Mycobacterium tuberculosis resistance to pretomanid in China

5/2024 - Annals of Clinical Micobiology and Antimicrobials

Author(s): Bing Zhao, Huiwen Zheng, Juliano Timm, Zexuan Song, Shaojun Pei, Ruida Xing, Yajie Guo, Ling Ma, Feina Li, Qing Li, Yan Li, Lin Huang, Chong Teng, Ni Wang, Aastha Gupta, Sandeep Juneja, Fei Huang, Yanlin Zhao, Xichao Ou

Tags: Drug-Sensitivity Testing, M.tb. Biology, MDR-TB, Pretomanid/PA-824, XDR-TB

Global adoption of 6-month drug-resistant TB regimens: Projected uptake by 2026

1/2024 - PLOS One

Author(s): A Gupta, S Juneja, V Babawale, N R Majidovich, N Ndjeka, P T M Nguyen, P Nargiza Nusratovna, D R Omanito, T T Pakasi, Y Terleeva, A Toktogonova, Y Waheed, Z Myint, Z Yanlin, S Sahu

Tags: Advocacy, Bedaquiline (TMC-207), BPaL, Linezolid, Moxifloxacin, Policy, Pretomanid/PA-824, TB Burden, TB Drug Market, TB Market

A novel home-based method for preparing suspensions of anti-TB drugs

11/2023 - International Journal of Tuberculosis and Lung Disease

Author(s): Taneja, R., Nahata, M. C., Scarim, J., Pande, P. G., Scarim, A., Hoddinott, G., Fourie, C. L., Jew, R. K., Schaaf, H. S., Hesseling, A. C., Garcia-Prats, A. J., Inabathina, K. Rao

Tags: BENEFIT Kids, Underserved Populations

Academia and industry agreement on a feasibility tool for first‐time‐in‐human clinical trial units

10/2023 - Clinical and Translational Science

Author(s): Paloma Moraga, Paula Prieto, Almari Conradie, Majda Benhayoun, Vicki Rousell, Maria Davy, Uwe Fuhr, Rosa Antonijoan Arbos, Francisco Abad‐Santos, Antonio Portolés, Jolanda Van Duinen, Antonio J. Carcas, Alberto M. Borobia, and the ERA4TB Consortium

Tags: Pharmacodynamics, Pharmacokinetics

The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis

10/2023 - Clinical Infectious Diseases

Author(s): Tasnim Hasan, Ellie Medcalf, Bern-Thomas Nyang'wa, Erica Egizi, Catherine Berry, Matthew Dodd, Salah Foraida, Medea Gegia, Mengchun Li, Fuad Mirzayev, Hannah Morgan, Ilaria Motta, Linh Nguyen, Samuel Schumacher, Tim Schlub, Greg Fox

Tags: Bedaquiline (TMC-207), BPaL, Linezolid, MDR-TB, Pretomanid/PA-824

Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid

10/2023 - PLOS Global Public Health

Author(s): Juliano Timm, Anna Bateson, Priya Solanki, Ana Paleckyte, Adam A Witney, Sylvia A D Rofael, Stella Fabiane, Morounfolu Olugbosi, Timothy D McHugh, Eugene Sun

Tags: Bedaquiline (TMC-207), BPaL, Linezolid, Pretomanid/PA-824

Community perspective on child-friendly medications for drug-resistant TB: importance, priorities and advocacy

9/2023 - International Journal of Tuberculosis and Lung Disease

Author(s): Viljoen, L., Acaba, J., Agbassi, Y. J. P., Beko, B., Goslett, C., Hoddinott, G., Kumar, B., Kumar, R. G., McKenna, L., Moses, G., Sachs, T., Seidel, S., von Delft, A.

Tags: Advocacy, BENEFIT Kids, Underserved Populations

YES, WE HAVE the POWER to END TB!

6/2023 - Indian Journal of Tuberculosis

Author(s): Nibedita Rath, Chaitali Nikam, Stephanie Seidel, Anindya Sinha, Vijay Arora

Tags: Advocacy, Community Engagement, TB Burden, Underserved Populations

Fed- and Fasted-State Performance of Pretomanid Amorphous Solid Dispersions Formulated with an Enteric Polymer

5/2023 - Molecular Pharmaceutics

Author(s): Hanh Thuy Nguyen, Tu Van Duong, Sarah Jaw-Tsai, Rebecca Bruning-Barry, Poonam Pande, Rajneesh Taneja, and Lynne S. Taylor

Tags: Pretomanid/PA-824, TB Drug Market, Underserved Populations

Stable compounded bedaquiline suspensions to support practical implementation of pediatric dosing in the field

3/2023 - International Journal of Tuberculosis and Lung Disease

Author(s): R Taneja, M C Nahata, J Scarim, P G Pande, A Scarim, G Hoddinott, C L Fourie, R K Jew, H S Schaaf, A J Garcia-Prats, A C Hesseling

Tags: Bedaquiline (TMC-207), BENEFIT Kids, Childhood TB, TB Burden, TB Market, Underserved Populations

Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model

3/2023 - Antimicrobial Agents and Chemotherapy

Author(s): Si-Yang Li, Paul J. Converse, Fabrice Betoudji, Jin Lee, Khisimuzi Mdluli, Anna Upton, Nader Fotouhi, Eric L. Nuermberger

Tags: Bedaquiline (TMC-207), BPaL, Clinical Development, Drug Discovery, Linezolid, Preclinical Data, Preclinical Models, Pretomanid/PA-824

Community engagement in tuberculosis research: the EU-Patient-cEntric clinicAl tRial pLatforms (EU-PEARL) experience

3/2023 - International Journal of Infectious Diseases

Author(s): Francesca Saluzzo, Juan Espinosa-Pereiro, Stephan Dressler, Ezio Tàvora Dos Santos Filho, Stephanie Seidel, Jesus Gonzalez Moreno, Norbert Heinrich, Adrian Sanchez-Montalva, Daniela Maria Cirillo

Tags: Advocacy, Clinical Development, Community Engagement, Trial Design, Underserved Populations

Extemporaneously compounded liquid formulations of clofazimine

2/2023 - International Journal of Tuberculosis and Lung Disease

Author(s): Taneja, R., Nahata, M. C., Scarim, J., Pande, P. G., Scarim, A., Hoddinott, G., Fourie, C. L., Jew, R. K., Schaaf, H. S., Hesseling, A. C., Garcia-Prats, A. J.

Tags: BENEFIT Kids, Childhood TB, Clofazamine, Underserved Populations

Assessing adverse events in clinical trials during the era of the COVID-19 pandemic

1/2023 - Journal of Biopharmaceutical Statistics

Author(s): James Buchanana, Mengchun Lib, Barbara Hendricksonc, Parul Bhargavad, Satrajit Roychoudhury

Tags: Trial Design

Comparison of pharmacokinetics and bioavailability of bedaquiline fumarate, benzoate and maleate in dogs

1/2023 - International Journal of Tuberculosis and Lung Disease

Author(s): Jaw-Tsai, S., Barry, R., Pande, P. G., Taneja, R., Yang, T.

Tags: Bedaquiline (TMC-207)

Sugar and sugar-free liquid formulations of delamanid for patients with rifampicin-resistant TB

1/2023 - International Journal of Tuberculosis and Lung Disease

Author(s): Taneja, R., Nahata, M. C., Scarim, J., Pande, P. G., Scarim, A., Hoddinott, G., Fourie, C. L., Jew, R. K., Schaaf, H. S., Garcia-Prats, A. J., Hesseling, A. C.

Tags: BENEFIT Kids, Childhood TB, Underserved Populations

Stable sugar and sugar-free suspensions of pretomanid

12/2022 - International Journal of Tuberculosis and Lung Disease

Author(s): Taneja, R., Nahata, M. C., Scarim, J., Pande, P. G., Scarim, A., Hoddinott, G., Fourie, C. L., Jew, R. K., Schaaf, H. S., Garcia-Prats, A. J., Hesseling, A. C.

Tags: BENEFIT Kids, Childhood TB, Pretomanid/PA-824, Underserved Populations

Characterizing Absorption Properties of Dispersible Pretomanid Tablets Using Population Pharmacokinetic Modelling

11/2022 - Clinical Pharmacokinetics

Author(s): Yuanxi Zou, Jerry Nedelman, Antonio Lombardi, Frances Pappas, Mats O Karlsson, Elin M Svensson

Tags: Pharmacokinetics, Pretomanid/PA-824

Lifesaving, cost-saving: Innovative simplified regimens for drug-resistant tuberculosis

11/2022 - PLOS Global Public Health

Author(s): Aastha Gupta, Sandeep Juneja, Suvanand Sahu, Mohammed Yassin, Grania Brigden, Eliud Wandwalo, Saurabh Rane, Fuad Mirzayev, Matteo Zignol

Tags: Bedaquiline (TMC-207), BPaL, Linezolid, Pretomanid/PA-824, TB Burden, TB Drug Market, TB Market

Pages